Treeline Biosciences
Biotechnology company developing precision medicines for cancer and other serious conditions using AI-driven drug discovery. Raised $621.8 million in Series A funding in September 2025, one of the largest Series A rounds in biotech history.
Notes
Treeline Biosciences is a biotechnology company developing precision medicines intended to treat cancer and other serious conditions. The company is headquartered in Cambridge, Massachusetts.
In September 2025, Treeline raised $621.8 million in Series A funding, making it one of the largest Series A rounds in biotechnology history. The round was led by Casdin Capital and Deerfield Management, reflecting strong investor confidence in the company's approach to precision medicine and drug discovery.
The company is leveraging AI and computational approaches to accelerate the discovery and development of targeted therapeutics for patients with cancer and other serious diseases.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Raised $621.8 million in Series A (September 2025)
- One of largest Series A rounds in biotech history
- Investors: Casdin Capital, Deerfield Management
- Focus on precision medicines for cancer
- AI-driven drug discovery
- Cambridge, Massachusetts headquarters
- Founded in 2022
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Casdin Capital | New York, USA | biotech-focused | series-cgrowth | 3 |
| Deerfield Management | New York, USA | biotech-focused | seedseries-a+3 | 3 |